Masimo (NASDAQ:MASI) Issues Q3 2024 Earnings Guidance

Masimo (NASDAQ:MASI) updated its third quarter 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.810-0.860 for the period, compared to the consensus earnings per share estimate of 0.830. The company issued revenue guidance of $495.0 million-$515.0 million, compared to the consensus revenue estimate of $502.2 million. Masimo also updated its Q3 guidance to $0.81-0.86 EPS.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on MASI shares. Needham & Company LLC reaffirmed a hold rating on shares of Masimo in a report on Friday, September 20th. Piper Sandler boosted their price target on Masimo from $160.00 to $165.00 and gave the company an overweight rating in a research note on Wednesday, August 7th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and an average target price of $144.67.

Masimo Stock Down 0.5 %

NASDAQ MASI opened at $133.10 on Friday. The stock’s 50 day simple moving average is $116.67 and its 200 day simple moving average is $124.97. Masimo has a one year low of $75.22 and a one year high of $153.93. The firm has a market cap of $7.08 billion, a PE ratio of 90.54 and a beta of 0.98. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.15.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The company had revenue of $496.30 million for the quarter, compared to analysts’ expectations of $493.92 million. During the same quarter in the prior year, the business earned $0.62 earnings per share. The business’s revenue for the quarter was up 9.0% on a year-over-year basis. As a group, sell-side analysts forecast that Masimo will post 3.87 earnings per share for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.